Moderna stock
MRNANASDAQModerna, Inc., HealthcareISIN US60770K1079
48Score 48 out of 100, Weak
Price and trend
86 / 100
Price history
+842% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 163% above it.
Since January 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 67).
The price is 7.6% below its 52-week high. Largest decline in 8 years: 95% (August 2021 to November 2025).
Chart figures for advanced users
- SMA 50$198.57
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$94.60
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)67
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$22.36
- The lowest closing price of the last twelve months.
- Resistance$269.00
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Moderna, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $100.63B, is number 2 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.94B (down 39.2% year on year) and a loss of $2.82B.
- For fiscal 2026, analysts expect on average revenue of $2.1B (up 8.1%) and adjusted earnings per share of −$8.42.
Show more
- MEQIRI Score 48 out of 100 (Weak): rank 405 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $5.17B, financial debt $4.18B.
Weaknesses
- Volatile share priceVolatility 194% a year over the last 12 months.Stability 48
- Loss-makingLoss of $2.79B over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$1.95B over the last 12 months.Fundamentals 17
Its standout strengths are momentum and technical analysis, while fundamentals and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue fell 39.2% on the prior year. Revenue has grown strongly since 2016, at around 38% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 55%, operating −158%, net −145%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 12 Feb 2027in 92 days
- Last reported
- 6 Nov 2026EPS reported $0.38 (expected −$1.10)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$8.42−1.2%
- Revenue
- $2.1B0.0%
- Earnings per share
- −$4.76−0.3%
- Revenue
- $2.43B+0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.8%Revenue growth of up to 10% in 2026 reiterated; cost guidance lowered by $0.2 billion, with cash and investments projected at $4.7 billion to $5.2 billion at year end.
“Cash and investments are now projected to be between $4.7 billion and $5.2 billion at the end of 2026, which reflect the improvement in our cash cost guidance. As a reminder, our cash guidance does not assume any additional drawdown from our remaining $0.9 billion undrawn credit facility.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 31 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $72.13M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Hoge StephenSale
15 Oct 2026, President
- Shares
- 39,145
- Price
- $220.72
- Value
- $8.64M
- Hoge StephenSale
14 Oct 2026, President
- Shares
- 39,224
- Price
- $213.48
- Value
- $8.37M
- Hoge StephenSale
15 Sept 2026, President
- Shares
- 40,281
- Price
- $146.07
- Value
- $5.88M
Show 9 more
- Hoge StephenSale
14 Sept 2026, President
- Shares
- 40,294
- Price
- $144.13
- Value
- $5.81M
- Mock James MSale
10 Sept 2026, Chief Financial Officer
- Shares
- 34,836
- Price
- $134.49
- Value
- $4.69M
- Klinger Shannon ThymeSale
1 Sept 2026, Chief Legal Officer
- Shares
- 3,471
- Price
- $139.95
- Value
- $485,766
- Bancel StephaneSale
5 Aug 2026, Chief Executive Officer
- Shares
- 499,246
- Price
- $57.52
- Value
- $28.72M
- Hoge StephenSale
15 Jul 2026, President
- Shares
- 53,336
- Price
- $67.60
- Value
- $3.61M
- Hoge StephenSale
15 Jun 2026, President
- Shares
- 53,336
- Price
- $51.37
- Value
- $2.74M
- Klinger Shannon ThymeSale
4 Jun 2026, Chief Legal Officer
- Shares
- 3,471
- Price
- $50.00
- Value
- $173,550
- Afeyan NoubarSale
21 May 2026, Board
- Shares
- 9,263
- Price
- $46.84
- Value
- $433,879
- Hoge StephenSale
15 May 2026, President
- Shares
- 53,336
- Price
- $48.40
- Value
- $2.58M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Moderna
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Vertex PharmaceuticalsVRTX $138.69B76
- Regeneron PharmaceuticalsREGN $99.23B81
- UCBUCB.BR $61.8B78
- argenxARGX $61.25B70
- Lonza GroupLONN.SW $55.85B63
- Samsung Biologics207940.KS $49.8B68
- BeOne MedicinesONC $44.88B70
- Revolution MedicinesRVMD $39.08B43
ETFs that hold Moderna
Held by 50 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 12.70% | 0.50% | €127.06M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 6.33% | 0.35% | €1.21B |
| iShares Healthcare Innovation UCITS ETF2B78 | 5.93% | 0.40% | €1.49B |
Show 5 more
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 2.59% | 0.49% | €318.39M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 1.40% | 0.15% | €3.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 1.34% | 0.43% | €2.48B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 1.34% | 0.15% | €592.11M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.93% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2024)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.